CNTO136/Sirukumab (#15-1210): A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder
PI: James Murrough, MD; Study Coordinator: Betsy Wade; Funding: Janssen
Description: Our purpose is to evaluate the efficacy of sirukumab as an adjunctive treatment to antidepressant therapy (monoameinergic antidepressant). We will administer sirukumab by subcutaneous injection three times during the 12-week double blind treatment period.
Main Inclusion: Primary major depressive disorder diagnosis, inadequate response to at least one and no more than three antidepressants in current episode of depression, currently receiving no more than two approved antidepressants for at least six weeks duration
Main Exclusion: any current co-morbid Axis I diagnosis (generalized anxiety disorder, PTSD, social anxiety disorder , panic disorder, or nicotine dependence), lifetime treatment with a monoclonal antibody (biologic), age of onset of depression after 55 years of age
Study Participation Length: about 24 weeks
Compensation for all study visits: $450
CTD (#10-0645): A Novel Cognitive Training Intervention for Depression
PI: Brian Iacoviello, PhD; Study Coordinator: Megan Hoch; Funding: National Alliance for Research on Schizophrenia and Depression, formerly the Brain and Behavior Research Foundation, and NIMH K23 Program
Description: We are investigating the efficacy of a novel cognitive training computer program in treating depression and improving working memory and attention.
Main Inclusion: Primary MDD diagnosis, current episode of depression less than five years in length, not currently taking psychotropic medication, no more than one previous failure of an antidepressant medication, between ages 18 and 55
Main Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, eating disorder diagnosis within the last five years, attention-deficit/hyperactivity disorder (ADHD) diagnosis, current diagnosis of a substance use disorder at screening or within six months prior to screening, any clinically significant axis II disorder, any unstable general medical condition, current use of a psychotropic medication.
Study Participation Length: six to seven weeks
Compensation for all study visits: $695
FAST-MAS: Phase 2A Study to Evaluate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders By Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry
PIs: Wayne Goodman, MD, and Dan Iosifescu, MD; Study Coordinator: Betsy Wade; Funding: National Institutes of Mental Health (NIMH)
Description: Our purpose is to investigate a drug (LY2456302) for the treatment of problems experiencing pleasure (anhedonia) in people with mood and anxiety disorders. The larger goal is to test whether we can establish proof of concept that kappa opioid receptor antagonists engage neural circuits involved in mediating the reward response. Participants receive either the study drug or placebo daily for eight weeks.
Main Inclusion: diagnosis of major depressive disorder, bipolar I or II (currently depressed), generalized anxiety disorder (GAD), social phobia, panic disorder, or PTSD, experiencing anhedonia,
Main Exclusion: current use of any antidepressant, antipsychotic, anxiolytic, anticonvulsant, mood stabilizing, muscle relaxant, centrally acting antihistaminergic, stimulant or insomnia medications, substance abuse disorder within last three months, history of unstable or untreated serious medical condition
Study Participation Length: three to four months
Compensation for all study visits: $570